Duke University biomedical engineers have been able to repair a defect responsible for one of the most common inherited disorders, Duchenne muscular dystrophy
Using a novel genetic ‘editing’ technique, Duke University biomedical engineers have been able to repair a defect responsible for one of the most common inherited disorders, Duchenne muscular dystrophy, in cell samples from Duchenne patients.
Instead of the common gene therapy approach of adding new genetic material to “override” the faulty gene, the Duke scientists have developed a way to change the existing mutated gene responsible for the disorder into a normally functioning gene. The Duke researchers believe their approach could be safer and more stable than current methods of gene therapy.
The researchers are now conducting further tests of this new approach in animal models of the disease.
Duchenne muscular dystrophy is a genetic disease affecting one in 3,600 newborn males. The genetic mutation is found on the X chromosome, of which males have only one copy. (Females, with two X chromosomes, presumably have at least one good copy of the gene.)
Patients with Duchenne muscular dystrophy cannot produce the protein known as dystrophin, which is essential in maintaining the structural integrity of muscle fibers. Over time, patients with the disorder suffer gradual muscle deterioration, which leads to paralysis and eventual death, usually by age 25.
“Conventional genetic approaches to treating the disease involve adding normal genes to compensate for the mutated genes,” said Charles Gersbach, assistant professor of biomedical engineering at Duke’s Pratt School of Engineering and Department of Orthopaedic Surgery and member of Duke’s Institute for Genome Sciences and Policy. “However, this can cause other unforeseen problems, or the beneficial effect does not always last very long.
“Our approach actually repairs the faulty gene, which is a lot simpler,” said David Ousterout, the Duke biomedical engineering graduate student in the Gersbach lab who led the work. “It finds the faulty gene, and fixes it so it can start producing a functional protein again.”
The results of the Duke study were published online in Molecular Therapy, the journal of the American Society for Gene and Cell Therapy. The project was supported by the Hartwell Foundation, the March of Dimes Foundation and the National Institutes of Health.
The Duke experiments, which were carried out in cell samples from Duchenne muscular dystrophy patients, were made possible by using a new technology for building synthetic proteins known as transcription activator-like effector nucleases (TALENs), which are artificial enzymes that can be engineered to bind to and modify almost any gene sequence.
These TALENs bind to the defective gene, and can correct the mutation to create a normally functioning gene.
“There is currently no effective treatment for this disease,” Gersbach said. “Patients usually are in a wheelchair by the age of ten and many die in their late teens or early twenties.”
Duchenne muscular dystrophy has been extensively studied by scientists, and it is believed that more than 60 percent of patients with this type of mutation can be treated with this novel genetic approach.
The Latest Bing News on:
Duchenne muscular dystrophy
- Gene Therapy Offers New Hope for Duchenne Muscular Dystrophy Patientson July 25, 2024 at 12:32 pm
Gene therapy approach developed offers new hope for those with Duchenne muscular dystrophy by restoring the full-length dystrophin protein.
- Duvyzat Now Available for Duchenne Muscular Dystrophyon July 25, 2024 at 11:32 am
Duvyzat ™ (givinostat) oral suspension is now available for the treatment of patients 6 years of age and older with Duchenne muscular dystrophy (DMD).
- Nonsteroidal Drug for Duchenne Launches with a $700,000 Price Tagon July 25, 2024 at 9:22 am
Duvyzat was approved in March 2024 and works to reduce the inflammation and loss of muscle experienced by patients with Duchenne muscular dystrophy.
- New gene therapy approach shows promise for Duchenne muscular dystrophyon July 25, 2024 at 6:37 am
Indiana University School of Medicine researchers have made a significant breakthrough in developing a new gene therapy approach that restores full-length dystrophin protein, which could lead to new ...
- Gene Therapy Approach Shows Promise for Muscular Dystrophyon July 25, 2024 at 2:37 am
Researchers have made a significant breakthrough in developing a new gene therapy approach that restores full-length dystrophin protein, which could lead to new treatments for people with Duchenne ...
- Breakthrough gene therapy restores dystrophin protein in Duchenne muscular dystrophyon July 24, 2024 at 7:39 pm
Indiana University School of Medicine researchers have made a significant breakthrough in developing a new gene therapy approach that restores full-length dystrophin protein, which could lead to new ...
- Catalyst sells Canadian rights to Duchenne drug to Kye Pharmaon July 24, 2024 at 11:22 am
Catalyst Pharmaceuticals (NASDAQ:CPRX) announced Wednesday an agreement to grant privately owned Kye Pharmaceuticals the Canadian commercial rights to its recently approved Duchenne muscular dystrophy ...
- Muscular Dystrophy Newson July 23, 2024 at 5:00 pm
Fusion of myoblasts, ... Blocking an Ion Channel Improves Muscle Function and Survival in Mice With Severe Duchenne Muscular Dystrophy Sep. 13, 2022 — Researchers report that an experimental ...
- Mom surprises teen son with a power wheelchair. His reaction will bring you to tearson July 23, 2024 at 2:55 pm
Andrew Palmer lives with a form of muscular dystrophy and can't walk. His mom surprised him with a power wheelchair and his reaction went viral.
- A New Approach in Gene Therapy for Muscular Dystrophyon July 23, 2024 at 8:10 am
Scientists have created a new gene therapy for Duchenne muscular dystrophy that may not only help stop the disease in MD patients, but might also help... | Genetics And Genomics ...
The Latest Google Headlines on:
Duchenne muscular dystrophy
[google_news title=”” keyword=”Duchenne muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Transcription activator-like effector nucleases
- Small Model Organisms as Versatile Research Toolson July 26, 2024 at 5:43 am
The top down genome editing process is a genome synthesis method that uses tools such as zinc finger nucleases, CRISPR-Cas9 systems, and transcription-activator-like effector nucleases to develop ...
- Applications of Gene Knockout and Knock-in Models in Disease Researchon July 15, 2024 at 6:38 am
Gene knockout models involve the deliberate inactivation of a specific gene, knock-in models are developed by inserting a specific gene into a particular location within the genome.
- Global Microbial Gene Editing Services Market: Projected to Reach USD 30.5 Billion by 2032on July 11, 2024 at 8:03 pm
Microbial Gene Editing Services Market poised to soar to a value of USD 30.5 billion by 2032 at a CAGR of 19%.
- EXCLUSIVE: Cibus Expands Intellectual Property Coverage For 10 Plant Gene Editing And Trait Familieson June 26, 2024 at 6:12 am
and Transcription activator-like effector nuclease (TALEN) technology. The patents announced solidify Cibus’ intellectual property depth, driving product development and highlighting the ...
- Cibus Expands its Intellectual Property Coverage for Plant Gene Editing and Traitson June 26, 2024 at 5:30 am
and Transcription activator-like effector nuclease (TALEN) technology. Greg Gocal, PhD, Co-Founder, Executive Vice President and Chief Scientific Officer at Cibus, commented, “The development of ...
- Gene Editing - Precise DNA Manipulationon June 11, 2024 at 11:03 pm
TALENs (Transcription Activator-Like Effector Nucleases) are another class of engineered DNA-binding proteins used for gene editing. TALENs consist of a TAL effector DNA-binding domain fused to a DNA ...
- TALEN: A Precise Gene Editing Tool for Biotechnologyon June 11, 2024 at 11:02 pm
Despite its advantages, TALEN also faces some challenges. The construction of TALEN proteins can be time-consuming and labor-intensive compared to other gene editing tools like CRISPR-Cas9.
- Driving the future of CAR-T cell therapieson June 11, 2019 at 12:11 pm
Whereas many in the field have used gene-editing technologies such as transcription activator-like effector nucleases (TALENs), zinc finger nucleases or CRISPR–Cas9 to eliminate the TCR gene ...
- From restriction enzymes to CRISPR-Cas9on January 21, 2018 at 12:49 am
Although there are different methods available for doing this, only a few research laboratories in the world are able to produce customized zinc finger nucleases. Transcription activator-like effector ...
- How genes are edited using CRISPR-Cas9on February 15, 2016 at 10:59 pm
Before CRISPR/Cas9, there were other gene-editing methods such as zinc finger nucleases (ZFNs) and transcription-activator-like effector nucleases (TALENs). CRISPR-Cas9 is considered revolutionary ...
The Latest Google Headlines on:
Transcription activator-like effector nucleases
[google_news title=”” keyword=”transcription activator-like effector nucleases” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]